A pilot randomized controlled trial comparing a novel compassion and metacognition approach for schizotypal personality disorder with a combination of cognitive therapy and psychopharmacological treatment

dc.contributor.authorCheli, Simone
dc.contributor.authorCavalletti, Veronica
dc.contributor.authorLysaker, Paul H.
dc.contributor.authorDimaggio, Giancarlo
dc.contributor.authorPetrocchi, Nicola
dc.contributor.authorChiarello, Francesca
dc.contributor.authorEnzo, Consuelo
dc.contributor.authorVelicogna, Francesco
dc.contributor.authorMancini, Francesco
dc.contributor.authorGoldzweig, Gil
dc.contributor.departmentPsychiatry, School of Medicine
dc.date.accessioned2023-10-31T10:17:38Z
dc.date.available2023-10-31T10:17:38Z
dc.date.issued2023-02-20
dc.description.abstractBackground: Schizotypal personality disorder is characterized by a pervasive pattern of maladaptive behavior that has been associated with the liability for schizophrenia. Little is known about effective psychosocial interventions. This pilot non-inferiority randomized controlled trial aimed to compare a novel form of psychotherapy tailored for this disorder and a combination of cognitive therapy and psychopharmacological treatment. The former treatment - namely, Evolutionary Systems Therapy for Schizotypy-integrated evolutionary, metacognitively oriented, and compassion focused approaches. Methods: Thirty-three participants were assessed for eligibility, twenty-four randomized on a 1:1 ratio, nineteen included in the final analysis. The treatments lasted 6 months (24 sessions). The primary outcome was change across nine measurements in personality pathology, the secondary outcomes were remission from diagnosis and pre-post changes in general symptomatology and metacognition. Results: Primary outcome suggested a non-inferiority of the experimental treatment in respect to control condition. Secondary outcomes reported mixed results. There was no significant difference in terms of remission, but experimental treatment showed a larger reduction of general symptomatology (η2 = 0.558) and a larger increase in metacognition (η2 = 0.734). Conclusions: This pilot study reported promising results about the effectiveness of the proposed novel approach. A confirmatory trial on large sample size is needed to provide evidence about relative effectiveness of the two treatment conditions.
dc.eprint.versionFinal published version
dc.identifier.citationCheli S, Cavalletti V, Lysaker PH, et al. A pilot randomized controlled trial comparing a novel compassion and metacognition approach for schizotypal personality disorder with a combination of cognitive therapy and psychopharmacological treatment. BMC Psychiatry. 2023;23(1):113. Published 2023 Feb 20. doi:10.1186/s12888-023-04610-5
dc.identifier.urihttps://hdl.handle.net/1805/36785
dc.language.isoen_US
dc.publisherBMC
dc.relation.isversionof10.1186/s12888-023-04610-5
dc.relation.journalBMC Psychiatry
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourcePMC
dc.subjectCompassion
dc.subjectEvolution
dc.subjectEvolutionary systems therapy for schizotypy
dc.subjectMetacognition
dc.subjectSchizotypal personality disorder
dc.subjectSchizotypy
dc.titleA pilot randomized controlled trial comparing a novel compassion and metacognition approach for schizotypal personality disorder with a combination of cognitive therapy and psychopharmacological treatment
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
12888_2023_Article_4610.pdf
Size:
1.54 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: